Dusquetide

Summary

Dusquetide (CHEMBL3545314) is a phase-3 clinical-stage protein; indicated across 2 conditions including stomatitis and behcet disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 553.7 Da · C25H47N9O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545314
Name	Dusquetide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	71722017
Molecular formula	C25H47N9O5
Molecular weight	553.7
InChIKey	ZUJBBVJXXYRPFS-DYKIIFRCSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)N

IUPAC name: (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide

Also known as: Arg-ile-val-pro-ala-nh2, Dusquetida, Dusquetide, IMX-942, SGX-94, SGX-942, SGX94, Sgx942, SGX942, DUSQUETIDE

Patent coverage: 69 distinct patent families (146 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 139 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stomatitis	2	MONDO:0004842	EFO:1001904
Behcet disease	2	MONDO:0007191	EFO:0003780

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03237325	PHASE3	COMPLETED	DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
NCT02013050	PHASE2	COMPLETED	A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
NCT06386744	PHASE2	COMPLETED	Dusquetide for the Treatment of Behcet’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).